99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: A validation study

Journal of Nuclear Medicine

Volumn 45, Issue 10, 2004, Pages 1647-1652

  Signore, Alberto ^a,e   Annovazzi, Alessio ^a   Barone, Raffaella ^a   Bonanno, Elena ^a,b   D'Alessandria, Calogero ^a   Chianelli, Marco ^c   Mather, Stephen J ^d   Bottoni, Ugo ^a   Panetta, Chiara ^a   Innocenzi, Daniele ^a   Scopinaro, Francesco ^a   Calvieri, Stefano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c REGINA APOSTOLORUM HOSPITAL   (Italy)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e POLICLINICO UMBERTO I   (Italy)

Author keywords

Interleukin 2; Melanoma; Scintigraphy; Tumor infiltrating lymphocytes

Indexed keywords

CONTRAST MEDIUM; INTERLEUKIN 2 TC 99M; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; INTERLEUKIN 2; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M INTERLEUKIN 2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SCINTIGRAPHY; SKIN DEFECT; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; FEASIBILITY STUDY; LYMPHOCYTE; METABOLISM; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SKIN TUMOR; T LYMPHOCYTE SUBPOPULATION; VALIDATION STUDY;

FEASIBILITY STUDIES; HUMANS; INTERLEUKIN-2; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; ORGANOTECHNETIUM COMPOUNDS; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 13544256702     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996;74:43-47.
2. Hakansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Hakansson L. Biochemotherapy of metastatic malignant melanoma: predictive value of tumour-infiltrating lymphocytes. Br J Cancer. 2001;85:1871-1877.
3. Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother. 2002;51:539-546.
4. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 183 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA. 1994;271:907-913.
5. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Ann Surg. 1998;228:307-319.
6. Tartour E, Blay JY, Dorval T, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol. 1996;14:1697-1703.
7. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;15:3477-3482.
8. Becker JC, Schwinn A, Dummer R, Burg G, Brocker EB. Tumour-infiltrating lymphocytes in primary melanoma: functional consequences of differential IL-2 receptor expression. Clin Exp Immunol. 1993;91:121-125.
9. 123I-Interleukin- 2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med Commun. 2003;24:305-316.
10. 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med Mol Imaging. 2003;30:374-382.
11. Aherne WA, Dunnill MS. Morphometry. London, U.K.: Edward Arnold Publishers, Ltd; 1982:24-26.
12. Chianelli M, Signore A, Fritzberg AR, Mather SJ. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol. 1997;24:579-586.
13. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 1993;73:5-8.
14. Rimoldi D, Salvi S, Hartmann F, et al. Expression of IL-2 receptors in human melanoma cells. Anticancer Res. 1993;13:555-564.
15. Trentin L, Zambello R, Bulian P, et al. Functional role of IL-2 receptors on tumour-infiltrating lymphocytes. Br J Cancer. 1994;69:1046-1051.
16. Thor Straten P, Becker JC, Guldberg P, Zeuthen J. In situ T cells in melanoma. Cancer Immunol Immunother. 1999;48:386-395.
17. Anegon I, Cuturi MC, Trinchieri G, Perussia B. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med. 1988;167:452-472.